Every material Form 8-K ABEONA THERAPEUTICS INC. has filed with the SEC since June 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Abeona reported third-quarter 2026 results, with net ZEVASKYN revenue of $13.5 million, up 18% from $11.4 million in the second quarter, and a net loss of $4.8 million, or $0.08 per share, compared with $20.2 million, or $0.35 per share, in the prior quarter. The company also announced the $20 million stock-based acquisition of ABO-801 and a $30 million private placement, which it said will fund pipeline development and ZEVASKYN commercialization.
Net ZEVASKYN revenue was $13.5 million in Q3 2026, up 18% from $11.4 million in Q2 2026; one treatment's revenue was not recognized because its batch did not meet the identity assay release criterion.
Net loss was $4.8 million ($0.08 per share) in Q3 2026, versus $20.2 million ($0.35 per share) in Q2 2026.
Cash, cash equivalents and short-term investments were $134.9 million at September 30, 2026, down from $146.8 million at June 30, 2026; the figure excludes the $30 million private placement completed after quarter end.
Abeona issued $20 million of common stock to Ellodi Pharmaceuticals for the ABO-801 asset, with no upfront cash, plus up to $60 million in additional milestone payments and royalties.
Abeona Therapeutics acquired APT-1011, now called ABO-801, a clinical-stage treatment candidate for eosinophilic esophagitis, from Ellodi Pharmaceuticals in exchange for 4,494,383 common shares valued at $20 million, with no upfront cash. The company also agreed to sell 6,400,000 shares and pre-funded warrants for 1,600,043 shares in a private placement for about $30 million, expected to close November 10, 2026, which will add new shares and dilute existing holders.
Ellodi receives 4,494,383 shares valued at $20 million, based on a 20-day VWAP ending the trading day before the November 6, 2026 closing date, and no upfront cash.
Further payments to Ellodi include $30 million upon FDA approval of a New Drug Application, up to $30 million on sales milestones, and tiered royalties in the low to mid teen percentages.
Private placement of 6,400,000 shares at $3.75 per share plus pre-funded warrants at $3.7499, with Morgan Stanley as sole placement agent and net proceeds for general corporate purposes including ZEVASKYN.
One-third of the upfront shares unlock at each of the 6-, 12- and 18-month anniversaries of closing; resale registration for the private placement shares is due within 15 days after closing.
Abeona Therapeutics furnished an updated investor presentation under Regulation FD, which it expects to use on September 15, 2026 at the H.C. Wainwright 28th Annual Global Investment Conference. The filing is a routine disclosure of presentation materials and reports no financial results, guidance, or transactions.
Updated investor presentation furnished as Exhibit 99.1, dated September 15, 2026
Presentation to be used at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026
Filing contains no financial results, guidance, or new transactions; signed by CFO Joseph Vazzano
Abeona Therapeutics reported second quarter 2026 net ZEVASKYN revenue of $11.4 million, up 31% from $8.7 million in the first quarter, while its net loss widened to $20.2 million, or $0.35 per share, from $17.1 million in the prior quarter. The company ended the quarter with $146.8 million in cash and short-term investments, down from $191.4 million at December 31, 2025, and said ZEVASKYN will have CMS NTAP status effective October 1, 2026.
Net ZEVASKYN revenue rose 31% quarter over quarter to $11.4 million; revenue was recognized for four of the five patients treated in the quarter
Net loss was $20.2 million, or $0.35 per share, versus $17.1 million, or $0.30 per share, in Q1 2026
Cash, cash equivalents and short-term investments totaled $146.8 million as of June 30, 2026, versus $191.4 million at December 31, 2025
ZEVASKYN receives CMS New Technology Add-On Payment status effective October 1, 2026
Abeona Therapeutics director Michael Amoroso resigned from the company's Board of Directors effective immediately on June 11, 2026, and also left the Nominating and Corporate Governance Committee. The filing says the resignation was not due to any disagreement with the company over operations, policies or practices, and cites personal reasons only.
Michael Amoroso resigned from the Board of Directors effective immediately, dated June 11, 2026
He also resigned from the Nominating and Corporate Governance Committee
The filing states no disagreement with the company on operations, policies or practices; reason given is personal
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ABEONA THERAPEUTICS INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →